| Q36062593 | "This is not me": patient, family, cultural and clinician considerations in cases of severe cancer-related debility |
| Q64094417 | , the 12 AME journal indexed in SCIE |
| Q112280911 | CBX3 is associated with metastasis and glutathione/glycosphingolipid metabolism in colon adenocarcinoma |
| Q112297081 | miR-4477b gene as a novel pathogenic mutation occurring during the transformation of colorectal adenoma into colorectal cancer |
| Q35029036 | A 26-year-old female with metastatic primary gastrointestinal malignancy presenting as menorrhagia |
| Q36097230 | A 37 year-old pregnant woman with pancreatic adeno-carcinoma treated with surgery and adjuvant chemotherapy: A case report and literature review |
| Q51732438 | A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. |
| Q60922813 | A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin |
| Q60922822 | A Simplified Peritoneal Sarcomatosis Score for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| Q90346427 | A brief overview of the use of proton beam radiotherapy for gastrointestinal cancers |
| Q92716634 | A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors |
| Q37723260 | A case of esophageal squamous cell intraepithelial neoplasia with positivity for type 16 human papillomavirus successfully treated with radiofrequency ablation. |
| Q90643967 | A case of gastric small cell carcinoma with metastases to bone and liver |
| Q42995999 | A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression |
| Q42995933 | A case of periampullary adenocarcinoma in neurofibromatosis type 1. |
| Q36666226 | A case of peripheral T-cell lymphoma, not otherwise specified in a HCV and HTLV-II-positive patient, diagnosed by abdominal fluid cytology |
| Q42170305 | A case report of HCC cutaneous metastasis |
| Q92716644 | A case report of paraneoplastic syndrome in β-hCG-secreting duodenal adenocarcinoma |
| Q37285942 | A case report of trastuzumab dose in gastric cancer |
| Q58806074 | A case-control study of the association between metabolic syndrome and colorectal cancer: a comparison of International Diabetes Federation, National Cholesterol Education Program Adults Treatment Panel III, and World Health Organization definitions |
| Q90643838 | A cellular and bioinformatics analysis of the SENP1 SUMO isopeptidase in pancreatic cancer |
| Q36936998 | A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature |
| Q92486907 | A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study |
| Q37131721 | A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer |
| Q36792356 | A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer |
| Q34234974 | A critical review of the role of local excision in the treatment of early (T1 and T2) rectal tumors |
| Q34484291 | A curious discourse of Krukenberg tumor: a case report |
| Q125377808 | A discussion of the gut microbiome’s development, determinants, and dysbiosis in cancers of the esophagus and stomach |
| Q37131701 | A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma |
| Q38562800 | A journey into insidious world of MALT lymphoma of the ileum: from the beginning to the end. |
| Q41598569 | A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma |
| Q112277954 | A microarray expression profile and bioinformatic analysis of circular RNA in human esophageal carcinoma |
| Q43136969 | A molecularly confirmed neuroendocrine tumor resulting from Lynch Syndrome |
| Q34343534 | A new experimental model to allow use of clinical-scale endoscopes in small-animal tumor models |
| Q34961992 | A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. |
| Q39080588 | A novel management of post-oesophagectomy gastro-pleural fistula |
| Q114047245 | A novel senescence-associated LncRNA signature predicts the prognosis and tumor microenvironment of patients with colorectal cancer: a bioinformatics analysis |
| Q40073318 | A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer |
| Q34484245 | A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer |
| Q47110205 | A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients |
| Q61804221 | A phase I trial of Proton stereotactic body radiation therapy for liver metastases |
| Q35419253 | A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy |
| Q36097259 | A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study |
| Q36097126 | A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma |
| Q34484232 | A population based analysis of prognostic factors in advanced biliary tract cancer |
| Q36937002 | A potential association between exposure to hepatitis B virus and small bowel adenocarcinoma |
| Q41598618 | A rare case of primary rectal squamous cell carcinoma diagnosed by endoscopic ultrasound |
| Q36936983 | A rare case of three different tumors in the same pancreatic specimen: a case report and brief review of the literature |
| Q102155236 | A retrospective study on the impact of the number of resected lymph nodes on the survival outcome of stage IV rectal cancer patients after preoperative therapy |
| Q37015703 | A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers |
| Q99580546 | A review of systemic therapy in biliary tract carcinoma |
| Q47272245 | A semi-automated assessment of sarcopenia using psoas area and density predicts outcomes after pancreaticoduodenectomy for pancreatic malignancy |
| Q41598591 | A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapy-resistant colorectal cancer liver metastases |
| Q36666634 | AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy |
| Q112284233 | ANTXR1 as a potential prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma identified by a weighted gene correlation network analysis |
| Q26772268 | Abdominal metastases from colorectal cancer: intraperitoneal therapy |
| Q90041967 | Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a National Cancer Database analysis |
| Q90643889 | Accuracy of nodal staging is influenced by sidedness in colon cancer |
| Q42761055 | Acute myeloid leukemia masquerading as hepatocellular carcinoma |
| Q39172125 | Acute pancreatitis as a complication of trans-arterial chemoembolization of hepatocellular cancer-case report and review of literature |
| Q45340414 | Adaptive radiation dose escalation in rectal adenocarcinoma: a review |
| Q64882934 | Adaptive radiation therapy for cervical esophageal cancer: dosimetric and volumetric analysis. |
| Q34234964 | Addressing sexual dysfunction in colorectal cancer survivorship care |
| Q36582574 | Adenocarcinoma associated with tail gut cyst |
| Q41891466 | Adenocarcinoma of the proximal rectum and synchronous non-Hodgkin's lymphoma |
| Q64094456 | Adherence to surveillance guidelines following colonic polypectomy is abysmal |
| Q33820788 | Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? |
| Q47132819 | Adjuvant chemotherapy and outcomes in esophageal carcinoma |
| Q39640548 | Adjuvant intraoperative post-dissectional tumor bed chemotherapy-A novel approach in treating midgut neuroendocrine tumors |
| Q89579777 | Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail |
| Q35851281 | Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. |
| Q65002906 | Adjuvant radiotherapy in oesophageal cancer with positive circumferential resection margins-recurrence and survival outcomes. |
| Q33593250 | Adjuvant therapy in biliary tract and gall bladder carcinomas: a review |
| Q37131705 | Administered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases |
| Q99580495 | Adult height is not associated with the risk of stomach cancer in a meta-analysis |
| Q52346990 | Advanced age does not increase morbidity in pancreaticoduodenectomy. |
| Q39025911 | Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States |
| Q47170497 | Advanced duodenal neoplasia and carcinoma in familial adenomatous polyposis: outcomes of surgical management. |
| Q90346418 | Advanced metastatic gastric adenocarcinoma identified within the placenta: a case report with literature review |
| Q39673531 | Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference |
| Q60922859 | Advances in surgery for pancreatic cancer |
| Q36936995 | Adverse health behaviours among colorectal cancer survivors: a case study from Iran |
| Q45386283 | Age and factors associated with access and time to post-operative adjuvant chemotherapy in colon cancer: a French epidemiological study |
| Q53077821 | Age-related rates of colorectal cancer and the factors associated with overall survival. |
| Q89579796 | Aggressive mutation in a familial adenomatous polyposis syndrome family: when phenotype guides clinical surveillance |
| Q99580504 | Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres |
| Q42201909 | Alcoholic liver disease - Hepatocellular carcinoma transformation |
| Q64094394 | Ampullary and pancreatic adenocarcinoma-a comparative study |
| Q102155262 | An alternative splicing signature model for predicting hepatocellular carcinoma-specific survival |
| Q55080792 | An assessment of candidate genes to assist prognosis in gastric cancer. |
| Q40987835 | An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses |
| Q128510134 | An unexpected case of large cell neuroendocrine carcinoma of the colon: a case report |
| Q64094450 | An unusual case of obstructive jaundice: ampullary Burkitt lymphoma |
| Q90643961 | An unusual case of primary acinar cell carcinoma of the liver and its treatment |
| Q64932682 | Anaemia and its effects on tumour regression grade and survival following chemotherapy in adenocarcinoma of the oesophagus. |
| Q47168517 | Anal condylomas: predictors of recurrence and progression to high-grade dysplasia/carcinoma in situ |
| Q112284226 | Analysis of dynamic molecular networks: the progression from colorectal adenoma to cancer |
| Q37723268 | Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer |
| Q92486893 | Analyzing the impact of neoadjuvant radiation dose on pathologic response and survival outcomes in esophageal and gastroesophageal cancers |
| Q90041974 | Anastomotic leak and neoadjuvant chemoradiotherapy in esophageal cancer |
| Q41809675 | Aorto-esophageal fistula: a rare fatal case caused by esophageal malignancy |
| Q55176373 | Appendiceal diverticulosis: a harbinger of underlying primary appendiceal adenocarcinoma? |
| Q94602757 | Application of photodynamic therapy for liver malignancies |
| Q99580667 | Application of the CARE guideline as reporting standard in the Journal of Gastrointestinal Oncology |
| Q43141154 | Applying tumor genotyping and new clinical approaches to the management of colorectal cancer |
| Q55256764 | Approach and management of checkpoint inhibitor-related immune hepatitis. |
| Q64094425 | Artonin E sensitizes TRAIL-induced apoptosis by DR5 upregulation and cFLIP downregulation in TRAIL-refractory colorectal cancer LoVo cells |
| Q38085569 | Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases |
| Q41812830 | Assessment of clinical benefit and quality of life in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of peritoneal carcinomatosis |
| Q92645677 | Assessment of the external validity of the AJCC 8th staging system for small intestinal adenocarcinoma: a time to reconsider the role of tumor location? |
| Q37131664 | Association between chronic hepatitis C and hepatitis C/HIV co-infection and the development of colorectal adenomas |
| Q34484320 | Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis |
| Q36097078 | Association of Technetium(99m) MAG-3 renal scintigraphy with change in creatinine clearance following chemoradiation to the abdomen in patients with gastrointestinal malignancies |
| Q90643955 | Asymptomatic esophageal glomus tumor: case report |
| Q128461029 | BMP6 inhibits gastric cancer growth and predicts good prognosis |
| Q26772276 | BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies |
| Q94602693 | BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer |
| Q37131718 | BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype |
| Q36162518 | Barrett's esophagus: A review of diagnostic criteria, clinical surveillance practices and new developments |
| Q37677524 | Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer |
| Q36097096 | Bax expression is a candidate prognostic and predictive marker of colorectal cancer |
| Q36097114 | Benign multicystic peritoneal mesothelioma: A rare case presenting as pneumoperitoneum and pneumotosis intestinalis |
| Q28066550 | Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers |
| Q28066095 | Beyond RAS and BRAF: a target rich disease that is ripe for picking |
| Q58806091 | Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition |
| Q90346402 | Bidirectional chemotherapy in patients with gastric cancer and peritoneal metastasis |
| Q42995965 | Bilateral above knee amputations after prolonged exposure to sorafenib and trebananib |
| Q37723271 | Biliary and gastric drainage in advanced pancreatic serous cystadenoma and portal hypertension in Von Hippel-Lindau syndrome |
| Q39289707 | Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications |
| Q41370712 | Biliary stents for pancreas cancer with obstruction: the problem with plastic |
| Q112290178 | Bioinformatical identification of key genes regulated by IGF2BP2-mediated RNA N6-methyladenosine and prediction of prognosis in hepatocellular carcinoma |
| Q33895597 | Biologic therapy in esophageal and gastric malignancies: current therapies and future directions |
| Q33895581 | Biological agents in gastrointestinal cancers: adverse effects and their management |
| Q39453583 | Biologics in bowel cancer |
| Q33895557 | Biologics in gastrointestinal and pancreatic neuroendocrine tumors |
| Q28072468 | Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others |
| Q42042357 | Bone marrow infiltration as the initial presentation of gastric signet ring cell adenocarcinoma |
| Q33895624 | Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas |
| Q93558249 | Book Review |
| Q90041950 | Brain metastasis and herniation in a patient with ampullary adenocarcinoma presenting with jaundice and memory loss: case report |
| Q33947983 | Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy |
| Q37131670 | Breast metastasis from recurrent gallbladder adenocarcinoma: a case report with review of the literature |
| Q47136271 | Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation |
| Q38936641 | CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer |
| Q47137619 | CT-based assessment of visceral adiposity and outcomes for esophageal adenocarcinoma |
| Q112298751 | CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma |
| Q42178150 | Ca19-9 and pancreatic cancer: Is it really that good? |
| Q55259105 | Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. |
| Q128542478 | Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study |
| Q36792342 | Can only chemoradiotherapy and chemotherapy treatment be applied to patients with rectal cancer who could not be operated? |
| Q36097180 | Can pancreaticoduodenectomy performed at a comprehensive community cancer center have comparable results as major tertiary center? |
| Q90041992 | Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation |
| Q47143110 | Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma |
| Q60922862 | Capecitabine-induced hypertriglyceridemia: a rare but clinically relevant treatment-related adverse event |
| Q35419294 | Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer |
| Q36792339 | Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy |
| Q37723262 | Carcinoma transverse colon masquerading as carcinoma gall bladder |
| Q92486916 | Cardiovascular complications of metastatic colorectal cancer treatment |
| Q47107059 | Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy |
| Q94602707 | Cause of death for elders with colorectal cancer: a real-world data analysis |
| Q64917315 | Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma. |
| Q36062576 | Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal |
| Q42022293 | Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. |
| Q36097087 | Challenges toward personalized treatment of localized colorectal cancer |
| Q37285980 | Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer |
| Q38064466 | Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature |
| Q36666694 | Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patients |
| Q37525315 | Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation |
| Q47101175 | Characterization of malignant gastrointestinal stromal tumors-a single center experience |
| Q113727807 | Characterization of somatic mutations and pathway alterations during hepatocellular carcinoma vascular invasion using next-generation sequencing |
| Q60922867 | Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer |
| Q64991263 | Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base. |
| Q26768402 | Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy |
| Q33593207 | Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function |
| Q58806053 | Chemotherapy re-challenge response rate in metastatic colorectal cancer |
| Q42919192 | Cholangiocarcinoma: treatment with sorafenib extended life expectancy to greater than four years |
| Q102155245 | CircTBL1XR1/miR-424 axis regulates Smad7 to promote the proliferation and metastasis of colorectal cancer |
| Q94602718 | Circulating TGF-β1 as the potential epithelial mesenchymal transition-biomarker for diagnosis of cholangiocarcinoma |
| Q60922815 | Circulating miRNAs in patients with Barrett's esophagus, high-grade dysplasia and esophageal adenocarcinoma |
| Q128461019 | Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report |
| Q99580638 | Circulating tumor DNA and plasma microsatellite instability during PD-1 blockade |
| Q102155263 | Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer |
| Q42193906 | Circulating tumor cells in biliary cancer: First step or false step? |
| Q36792372 | Clinical applications of gene expression in colorectal cancer |
| Q28073730 | Clinical applications of liquid biopsies in gastrointestinal oncology |
| Q94602701 | Clinical characteristics and predictors of 5-year survival among colorectal cancer patients in a tertiary hospital in Malaysia |
| Q37677555 | Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience |
| Q37677520 | Clinical characteristics of adenosquamous esophageal carcinoma |
| Q94602703 | Clinical efficacy and quality of life after transrectal natural orifice specimen extraction for the treatment of middle and upper rectal cancer |
| Q90346372 | Clinical factors associated with the development of postoperative atrial fibrillation in esophageal cancer patients receiving multimodality therapy before surgery |
| Q64976017 | Clinical fate of T0N1 esophageal cancer: results from the National Cancer Database. |
| Q55714597 | Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. |
| Q38937672 | Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. |
| Q99580477 | Clinical outcomes of capecitabine-based versus S-1-based regimens as first-line chemotherapy in patients with unresectable or metastatic gastric cancer: a propensity score matched single-center comparison |
| Q90643912 | Clinical outcomes of endoscopic submucosal tunnel dissection compared with conventional endoscopic submucosal dissection for superficial esophageal cancer: a systematic review and meta-analysis |
| Q38937667 | Clinical outcomes of pancreaticoduodenectomy in octogenarians: a surgeon's experience from 2007 to 2015. |
| Q47133971 | Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. |
| Q38340526 | Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? |
| Q112287375 | Clinical values and potential pathways of miR-183-5p in gastric cancer: a study based on integrational bioinformatics analysis |
| Q37525363 | Clinical, morphologic, and immunophenotypic characteristics of ampullary carcinomas with an emphasis on SMAD4 expression. |
| Q36582564 | Clinically undiagnosed enteropathy associated T-cell lymphoma type II presenting with prolonged lower gastrointestinal tract symptoms: report of an autopsy case and review of diagnostic challenges and clinicopathological correlation. |
| Q58806066 | Clinicopathologic features and outcomes of gastrointestinal stromal tumors arising from the esophagus and gastroesophageal junction |
| Q37677515 | Clinicopathologic study of neuroendocrine tumors of gastroenteropancreatic tract: a single institutional experience |
| Q64955459 | Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. |
| Q41894931 | Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database |
| Q112644965 | Co-amplification of genes in chromosome 8q24: a robust prognostic marker in hepatocellular carcinoma |
| Q41829852 | Coexistence of gastrointestinal stromal tumour and colorectal adenocarcinoma: Two case reports |
| Q38795372 | Coexistence of intestinal Kaposi sarcoma and plasmablastic lymphoma in an HIV/AIDS patient: case report and review of the literature |
| Q61804222 | Colon cancer laterality is associated with atherosclerosis and coronary artery disease |
| Q37525310 | Colorectal cancer anatomic distribution patterns remain the same after sessile serrated adenoma/polyp considered cancer precursor: a 9-year comparison study from community-based endoscopy centers |
| Q42109814 | Colorectal cancer screening using protected microRNAs |
| Q34642007 | Colorectal carcinoma: Pathologic aspects |
| Q55283264 | Colorectal lymphoma in Mexico: clinico-pathological and survival analysis. |
| Q60922811 | Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle |
| Q94602716 | Combined conventional transarterial chemoembolization with Mitomycin and percutaneous ablation for unresectable hepatocellular carcinoma |
| Q33593231 | Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion |
| Q97525313 | Combined endo-laparoscopic surgery for difficult benign colorectal polyps |
| Q112281225 | Combined screening analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma |
| Q112726059 | Combined targeting of vascular endothelial growth factor C (VEGFC) and P65 using miR-27b-3p agomir and lipoteichoic acid in the treatment of gastric cancer |
| Q33948049 | Common hepatic duct stricture: are lithiasis and negative brush cytology enough to rule out Klatskin tumor? |
| Q112290649 | Comparative analysis of clinical, treatment, and survival characteristics of signet ring cell and adenocarcinoma of esophagus |
| Q35419331 | Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction |
| Q38827631 | Comparative effectiveness of chemopreventive interventions for colorectal cancer: protocol for a systematic review and network meta-analysis of randomised controlled trials. |
| Q102155266 | Comparison between B-mode ultrasonography and contrast-enhanced ultrasonography for the surveillance of early stage pancreatic cancer: a retrospective study |
| Q36097245 | Comparison of adiponectin concentration between pancreatic cancer and colorectal cancer |
| Q36062623 | Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center. |
| Q92486851 | Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer |
| Q33895614 | Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer |
| Q37131678 | Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma |
| Q55400693 | Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study. |
| Q99580518 | Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma |
| Q64094433 | Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis |
| Q92716689 | Complete mesocolic excision for colon cancer: is it worth it? |
| Q52725075 | Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer. |
| Q37522236 | Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6 |
| Q61804252 | Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome |
| Q112287379 | Comprehensive analysis of immune related lncRNAs in the tumor microenvironment of stage II-III colorectal cancer |
| Q112284232 | Comprehensive analysis of prognostic value and immune infiltration of calpains in pancreatic cancer |
| Q102155246 | Comprehensive analysis of the prognosis for chromobox family in gastric cancer |
| Q112645654 | Comprehensive analysis of the prognostic value of the chemokine-like factor-like MARVEL transmembrane domain-containing family in gastric cancer |
| Q112298753 | Comprehensive analysis of the relationship between competitive endogenous RNA (ceRNA) networks and tumor infiltrating-cells in hepatocellular carcinoma |
| Q112280909 | Comprehensive bioinformatics analysis of functional molecules in colorectal cancer |
| Q99580563 | Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer |
| Q112295175 | Comprehensive transcriptome analysis of colorectal cancer risk of hyperglycemia in humans |
| Q92645740 | Concomitant KRAS and BRAF mutations in colorectal cancer |
| Q58806092 | Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas |
| Q33593181 | Concurrent chemoradiation with volumetric modulated Arc therapy of patients treated for anal cancer-acute toxicity and treatment outcome |
| Q34962131 | Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer |
| Q36936990 | Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma |
| Q36666214 | Consensus and conflict in invasive micropapillary carcinoma: a case report and review of the literature |
| Q112287383 | Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation |
| Q37131686 | Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. |
| Q43090484 | Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer |
| Q47098835 | Contrast enhanced ultrasound guided biopsies of liver lesions not visualized on standard B-mode ultrasound-preliminary experience |
| Q112293397 | Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining |
| Q64094402 | Correlation between endoscopic features of the anastomosis after low anterior resection and postsurgical anorectal function |
| Q60922844 | Correlation between vascular endothelial growth factor-A expression and tumor location and invasion in patients with colorectal cancer |
| Q47151468 | Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer |
| Q90041985 | Correlation of tumor size and survival in pancreatic cancer |
| Q39453613 | Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma |
| Q64942166 | Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer. |
| Q94602743 | Could CTSK and COL4A2 be specific biomarkers of poor prognosis for patients with gastric cancer in Asia?-a microarray analysis based on regional population |
| Q99580507 | Critical evaluation of quality of hepatopancreatic surgery in a medium-volume center in Finland using the Accordion Severity Grading System and the Postoperative Morbidity Index |
| Q61804236 | Curative treatment for metastatic colorectal cancer in the young population: is it worth it? |
| Q33948033 | Current and future systemic treatment options in metastatic pancreatic cancer |
| Q39453572 | Current biologics for treatment of biliary tract cancers |
| Q39172118 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie |
| Q114593251 | Current data is sufficient to recommend a current standard of care |
| Q46711258 | Current multidisciplinary oncology series. |
| Q52643527 | Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. |
| Q97525363 | Current status of laparoscopic liver resection for the management of colorectal liver metastases |
| Q34962039 | Current status of novel agents in advanced gastroesophageal adenocarcinoma |
| Q33820782 | Current strategies in chemoradiation for esophageal cancer |
| Q36097192 | Current surgical management of pancreatic cancer |
| Q90042007 | Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States |
| Q26749000 | Cutaneous manifestation of gastrointestinal disease |
| Q41598532 | Cyclooxygenase-2 gene polymorphisms and susceptibility to colorectal cancer in a Brazilian population. |
| Q43136882 | Cytopathologic diagnosis of liver mass lesions |
| Q36792361 | Cytopathology of the pancreatobiliary tract-the agony, and sometimes, the ease of it. |
| Q41598550 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with two-stage hepatectomy for multiple and bilobar desmoplastic small round cell tumor liver metastases. |
| Q26768376 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection |
| Q26768312 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time? |
| Q38461836 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy |
| Q55258604 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience. |
| Q26768309 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality |
| Q37285937 | Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal and hepatic metastases: a case-control study. |
| Q26768296 | Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future |
| Q112719932 | DAPT suppresses proliferation and migration of hepatocellular carcinoma by regulating the extracellular matrix and inhibiting the Hes1/PTEN/AKT/mTOR signaling pathway |
| Q92716629 | DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer |
| Q60922854 | Daily breathing inconsistency in pancreas SBRT: a 4DCT study |
| Q90643870 | Decreased percentage of neutrophil is a predict factor for the efficacy of trifluridine and tipiracil hydrochloride for pretreated metastatic colorectal cancer |
| Q37677544 | Defining the distal margin of rectal cancer for surgical planning |
| Q36062603 | Delayed diagnosis of pancreatic cancer reported as more common in a population of North African young adults |
| Q90643923 | Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting |
| Q47107946 | Demographic and clinical factors associated with suicide in gastric cancer in the United States |
| Q89579767 | Demographic characteristics and the first program of colorectal cancer (CRC) screening in north of Iran (2016) |
| Q60922855 | Demographic disparities in delay of definitive chemoradiation for anal squamous cell carcinoma: a nationwide analysis |
| Q37677542 | Depression, anxiety, and health related quality of life among colorectal cancer survivors |
| Q55452827 | Detecting promoter methylation pattern of apoptotic genes Apaf1 and Caspase8 in gastric carcinoma patients undergoing chemotherapy. |
| Q36097264 | Detection of circulating tumor cells in cancers of biliary origin |
| Q42238122 | Detection of circulating tumor cells in gastrointestinal cancer: Has its time come? |
| Q41853963 | Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib |
| Q36936943 | Determining the optimal number of lymph nodes harvested during esophagectomy |
| Q55292088 | Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. |
| Q112642599 | Development and verification of a hypoxia- and immune-associated prognosis signature for esophageal squamous cell carcinoma |
| Q26749007 | Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD) |
| Q26799442 | Diagnosis and management of cystic lesions of the pancreas |
| Q26768364 | Diagnosis and management of patients with malignant peritoneal mesothelioma |
| Q92716679 | Diagnostic and management strategies for lateral pelvic lymph nodes in low rectal cancer-a review of the evidence |
| Q34658072 | Diet and supplements and their impact on colorectal cancer |
| Q90346342 | Difference in toxicity between HIV-positive and HIV-negative patients with squamous-cell cancer of the anal canal treated with concomitant radio-chemotherapy |
| Q90041896 | Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma |
| Q37677564 | Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy |
| Q36792368 | Differential lymph node retrieval in rectal cancer: associated factors and effect on survival |
| Q36936972 | Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience |
| Q37525373 | Diminished expression of MGMT & RASSF1A genes in gastric cancer in ethnic population of Kashmir |
| Q92486918 | Direct oral anticoagulants in gastrointestinal malignancies: is the convenience worth the risk? |
| Q36666667 | Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. |
| Q99580528 | Discovery of a novel three-long non-coding RNA signature for predicting the prognosis of patients with gastric cancer |
| Q92486861 | Disparities in colon and rectal cancer queried individually between Hispanics and Whites |
| Q89579781 | Disparities in major surgery for esophagogastric cancer among hospitals by case volume |
| Q37525301 | Disparities in receipt of radiotherapy and survival by age, sex, and race among patients with non-metastatic squamous cell carcinoma of the anus |
| Q53699565 | Disparities in resection of hepatic metastases in colon cancer. |
| Q55032185 | Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum. |
| Q36097082 | Do all locally advanced rectal cancers require radiation? A review of literature in the modern era. |
| Q64094399 | Do clinicopathologic features of rectal and colon cancer guide us towards distinct malignancies? |
| Q55640874 | Does a fine line exist between regional and metastatic pelvic lymph nodes in rectal cancer-striking discordance between national guidelines and treatment recommendations by US radiation oncologists. |
| Q64094444 | Does a stoma reduce the risk of anastomotic leak and need for re-operation following low anterior resection for rectal cancer: systematic review and meta-analysis of randomized controlled trials |
| Q47126414 | Does histology really influence gastric cancer prognosis? |
| Q41598646 | Does lymphocyte-to-monocyte ratio before, during, or after definitive chemoradiation for locally advanced pancreatic cancer predict for clinical outcomes? |
| Q128461028 | Does microbiota composition act as predictive signature for the evaluation of chemoimmunotherapy response efficacy? |
| Q42053185 | Does postoperative radiation therapy benefit patients with esophageal cancer? |
| Q90643906 | Does the addition of adjuvant intraoperative tumor bed chemotherapy during midgut neuroendocrine tumor debulking procedures benefit patients? |
| Q64997389 | Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. |
| Q33432931 | Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial |
| Q90346360 | Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia |
| Q99580515 | Down-regulation of small nuclear RNA (snRNA) RNU5E-1 in hepatocellular carcinoma presents with vital clinical significance |
| Q90346382 | Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience |
| Q36666629 | Drain amylase aids detection of anastomotic leak after esophagectomy. |
| Q36062580 | Duodenal and gallbladder metastasis of regressive melanoma: a case report and review of the literature |
| Q35419376 | Duodenojejunal flexure tumors: surgical difficulties with case series |
| Q41894920 | Durable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal stromal tumor |
| Q37677567 | EBV-associated hepatic smooth muscle tumor of uncertain biologic behavior after heart transplantation in a pediatric patient: case report |
| Q39025928 | EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. |
| Q36097220 | EUS and pancreatic cyst fluid analysis: Is the juice worth the aqueeze? |
| Q55365705 | Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy. |
| Q37522227 | Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review |
| Q33895629 | Effect of Helicobacter pylori infection on outcomes in resected gastric and gastroesophageal junction cancer |
| Q90643875 | Effect of KRAS mutational status on disease behavior and treatment outcome in patients with metastatic colorectal cancer: intratumor heterogeneity and mutational status |
| Q37525281 | Effect of gender on psychosocial adjustment of colorectal cancer survivors with ostomy |
| Q36582536 | Effectiveness of early and aggressive administration of fresh frozen plasma to reduce massive blood transfusion during cytoreductive surgery |
| Q36097269 | Effectiveness of radiation therapy in GIST: A case report |
| Q122643773 | Effects of magnetic resonance imaging (MRI)-detected extramural vascular invasion (mrEMVI) and tumor deposits (TDs) on distant metastasis and long-term survival after surgery for stage III rectal cancer: a retrospective study grouped based on the re |
| Q64094374 | Effects of oxaliplatin-containing adjuvant chemotherapy on short-term survival of patients with colon cancer in Dr. Sardjito Hospital, Yogyakarta, Indonesia |
| Q58806056 | Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
| Q35028999 | Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. |
| Q38027518 | Emergency surgery for perforated gastric malignancy: An institution's experience and review of the literature |
| Q36097144 | Emerging therapies in pancreas cancer |
| Q41598584 | Endocuff assisted colonoscopy significantly increases sessile serrated adenoma detection in veterans |
| Q92486896 | Endoscopic and clinicopathological characteristics of gastrointestinal adult T-cell leukemia/lymphoma |
| Q41886474 | Endoscopic innovation through animal experiments: a new in-vitro platform. |
| Q26998802 | Endoscopic options for early stage esophageal cancer |
| Q42111209 | Endoscopic sealing of a rectovesical fistula with a combination of an over the scope clip and cyano-acrylate injection. |
| Q92716666 | Endoscopic stenting in colorectal cancer |
| Q90041905 | Endoscopic stenting should be advocated in patients with stage IV colorectal cancer presenting with acute obstruction |
| Q35158524 | Endoscopic stenting versus operative gastrojejunostomy for malignant gastric outlet obstruction-a systematic review and meta-analysis of randomized and non-randomized trials |
| Q102155244 | Endoscopic submucosal dissection in the treatment of patients with early colorectal carcinoma and precancerous lesions |
| Q39408683 | Endoscopic ultrasonography for pancreatic cancer: current and future perspectives |
| Q39025906 | Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics |
| Q38860994 | Endoscopic versus surgical resection for early colorectal cancer-a systematic review and meta-analysis. |
| Q99580491 | Enhanced fatty acid oxidation mediated by CPT1C promotes gastric cancer progression |
| Q42332772 | Entering the molecular era of gastrointestinal oncology: current updates and challenges |
| Q40048465 | Epidemiological profile of gastric cancer in the northwestern region of Algeria: about 116 cases |
| Q89461599 | Erratum to "Osteonecrosis of the jaw associated with ziv-aflibercept" |
| Q87032700 | Erratum to A case of esophageal squamous cell intraepithelial neoplasia with positivity for type 16 human papillomavirus successfully treated with radiofrequency ablation |
| Q55290632 | Erratum to updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. |
| Q43106527 | Esophageal cancer 2015, more questions than answers |
| Q42238015 | Esophageal cancer: Is preoperative chemoradiation the new standard? |
| Q90041980 | Esophagectomy from then to now |
| Q42399152 | Esophagojejunal anastomosis leakage after total gastrectomy for esophagogastric junction adenocarcinoma: options of treatment |
| Q36062572 | Establishing the link between hepatitis B virus infection and colorectal adenoma |
| Q55338874 | Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients. |
| Q112287617 | Establishment and verification of a prognostic tumor microenvironment-based and immune-related gene signature in colon cancer |
| Q112570591 | Estimating the prognosis of esophageal squamous cell carcinoma based on The Cancer Genome Atlas (TCGA) of m6A methylation-associated genes |
| Q94602713 | Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index |
| Q37723254 | Ethnic disparities in the risk of colorectal adenomas associated with aspirin and statin use: a retrospective multiethnic study |
| Q112644012 | Evaluating prognostic value and relevant gene signatures of tumor microenvironment characterization in esophageal carcinoma |
| Q102155252 | Evaluating the effect of diabetes on the prognosis of gastric cancer using a propensity score matching method |
| Q94602697 | Evaluating treatment protocols for rectal squamous cell carcinomas: the Duke experience and literature |
| Q36062598 | Evaluation and comparison of postoperative levels of serum bilirubin, serum transaminases and alkaline phosphatase in laparoscopic cholecystectomy versus open cholecystectomy |
| Q53176896 | Evaluation of altered expression of miR-9 and miR-106a as an early diagnostic approach in gastric cancer. |
| Q64996501 | Evaluation of confocal endoscopic microscopy for detection of early-stage gastric cancer in hereditary diffuse gastric cancer (HDGC) syndrome. |
| Q42076368 | Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848. |
| Q64885732 | Evaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study. |
| Q36582547 | Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma |
| Q33947977 | Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: impact of patient education before treatment initiation |
| Q47143264 | Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma |
| Q38398872 | Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET. |
| Q58806080 | Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline mutation |
| Q35028994 | Exfoliative erythroderma as a paraneoplastic presentation of adenocarcinoma of the gallbladder |
| Q92486885 | Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma |
| Q121890373 | Exosomal miR-125b-5p derived from cancer-associated fibroblasts promotes the growth, migration, and invasion of pancreatic cancer cells by decreasing adenomatous polyposis coli (APC) expression |
| Q36097215 | Exosome can prevent RNase from degrading microRNA in feces |
| Q35029010 | Exploring signet-ring cells in pregnant female |
| Q60922851 | Exploring the differences between early-onset gastric cancer and traditional-onset gastric cancer |
| Q102155250 | Expression and prognostic value of Chromobox family members in gastric cancer |
| Q36666613 | Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma |
| Q60922842 | Expression of miR-520c in intestinal type gastric adenocarcinoma |
| Q28087333 | Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers |
| Q60922869 | External validation of the 8 American Joint Committee on Cancer staging system for gall bladder carcinoma |
| Q36381234 | Extra Gastrointestinal Stromal Tumor treated with imatinib in a patient with Neurofibromatosis type 1. |
| Q43014471 | Extramedullary plasmacytoma of the gallbladder diagnosed by endoscopic ultrasound fine needle aspiration (EUS-FNA). |
| Q112644014 | FAT10 promotes hepatocellular carcinoma (HCC) carcinogenesis by mediating P53 degradation and acts as a prognostic indicator of HCC |
| Q42238036 | FDG PET imaging in the staging and management of gastric cancer |
| Q55190760 | FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. |
| Q102155230 | Factors associated with worse outcomes for colorectal neuroendocrine tumors in radical versus local resections |
| Q35029020 | Factors influencing response to neoadjuvant chemoradiation and outcomes in rectal cancer patients: tertiary Indian cancer hospital experience |
| Q37677546 | Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). |
| Q40942790 | Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus |
| Q37131693 | Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer |
| Q64949380 | Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. |
| Q41598516 | Feasibility and reproducibility of substituting oral contrast with water for duodenal volume delineation in patients undergoing pancreatic stereotactic body radiotherapy |
| Q92486902 | Feasibility of circulating tumor DNA testing in hepatocellular carcinoma |
| Q92645679 | Fibroblast growth factor 7 signalling is disrupted in colorectal cancer and is a potential marker of field cancerisation |
| Q36582559 | Fine needle aspiration biopsy of malignant mass lesions in the liver: a revisit of diagnostic profiles and challenges |
| Q90643895 | First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age |
| Q41918211 | Fluid analysis prior to surgical resection of suspected mucinous pancreatic cysts. A single centre experience |
| Q47177827 | Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm |
| Q37522222 | Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis |
| Q41894903 | Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study. |
| Q92486905 | Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review |
| Q39640894 | Functional imaging of radiation liver injury in a liver metastasis patient: imaging and pathologic correlation |
| Q38856650 | Functioning gangliocytic paraganglioma of the ampulla: clinicopathological correlations and cytologic features |
| Q64094406 | GSTM1 and GSTT1 copy number variants and the risk to Thai females of hepatocellular carcinoma |
| Q36936960 | Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India |
| Q60922818 | Gastric adenocarcinoma revealed by atypical pulmonary lymphangitic carcinomatosis |
| Q37723251 | Gastric cancer-a clinicopathological study in a tertiary care centre of North-eastern India |
| Q34642023 | Gastric cancer: Classification, histology and application of molecular pathology |
| Q42125510 | Gastric cancer: toward a cisplatin-free disease? |
| Q33948007 | Gastric metastasis of Merkel cell carcinoma, a rare cause of gastrointestinal bleeding: case report and review of the literature |
| Q37677532 | Gastric metastasis of bilateral breast cancer |
| Q61804249 | Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis |
| Q37525329 | Gastrointestinal lymphoma in Western Algeria: pattern of distribution and histological subtypes (retrospective study). |
| Q36162485 | Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features |
| Q84922596 | Gastrointestinal stromal tumor |
| Q38795364 | Gastrointestinal stromal tumor with an unusual presentation as an enlarged prostate gland: a case report and review of the literature |
| Q33895608 | Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review |
| Q54958698 | Gastrointestinal stromal tumors in the imatinib era: 15 years' experience of a tertiary center. |
| Q61804247 | Gastrointestinal stromal tumors: a comprehensive review |
| Q55714953 | Gastrointestinal stromal tumours: advances in surgical and pharmacological management options. |
| Q37522211 | Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. |
| Q40054530 | Gemcitabine and capecitabine for advanced biliary cancer |
| Q36792347 | Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC). |
| Q33443909 | Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response |
| Q92645687 | Gender differences in health-related quality of life among patients with colorectal cancer |
| Q90346355 | Gene mutations distinguishing gastric from colorectal and esophageal adenocarcinomas |
| Q97525403 | Genetic and epigenetic alterations in pancreatic neuroendocrine tumors |
| Q36162532 | Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine |
| Q90643842 | Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy |
| Q38859321 | Genomic profiling of high-grade large-cell neuroendocrine carcinoma of the colon |
| Q92716660 | Genomics and metagenomics of colorectal cancer |
| Q55668963 | Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. |
| Q36381209 | Giant mucinous cystic neoplasms of pancreas and liver with unusual adipose tissue component: a case report |
| Q41849260 | Giving oligometastases the best shot using stereotactic body radiosurgery with image guidance. How far is the cat out of the bag? |
| Q38225134 | HDR brachytherapy for anal cancer |
| Q47126199 | HER-2/neu gene amplification in gastric adenocarcinoma and its relationship with clinical and pathological findings |
| Q35029025 | HER2 expression in gastric and oesophageal cancer: a meta-analytic review |
| Q37522215 | HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis |
| Q34484252 | HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report |
| Q30465632 | HIFU for palliative treatment of pancreatic cancer |
| Q34640551 | HIV- positive anal cancer: an update for the clinician |
| Q26749003 | Health disparities in colorectal cancer among racial and ethnic minorities in the United States |
| Q102155240 | Health economic evaluation of patients with sepsis after gastrointestinal tumor surgery-a cost consequences analysis in China |
| Q47110681 | Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now. |
| Q90346472 | Heavy charged particles for gastrointestinal cancers |
| Q36381202 | Helicobacter pylori infection and colorectal carcinoma: is there a causal association? |
| Q41370912 | Helicobacter pylori infection and colorectal carcinoma: pathologic aspects |
| Q64906284 | Hematologic markers of distant metastases in gastric cancer. |
| Q121811530 | Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan |
| Q36352452 | Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases |
| Q92716717 | Hepatic metastasis from colorectal cancer |
| Q38027521 | Hepatic necrosis and hemorrhage following hyperthermic intraperitoneal chemotherapy with oxaliplatin: A review of two cases |
| Q26772267 | Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer |
| Q46290290 | Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care Kelly M. McMasters and Jean-Nicolas Vauthey, editors. |
| Q39289689 | Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. |
| Q36097273 | Hepatoid adenocarcinoma of the peritoneal cavity: Prolonged survival after debulking surgery and 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) therapy |
| Q33408164 | Hepatosplenic alpha/beta T-cell lymphoma masquerading as cirrhosis |
| Q99580439 | High body mass index is associated with an increased overall survival in rectal cancer |
| Q37677527 | High dose chemoradiation for unresectable hilar cholangiocarcinomas using intensity modulated external beam radiotherapy: a single tertiary care centre experience |
| Q112284230 | High expression of MAGE-C1 gene in colorectal cancer is associated with its poor prognosis |
| Q112284236 | High expression of Ran binding protein 1 predicts poor outcomes in hepatocellular carcinoma patients: a Cancer Genome Atlas database analysis |
| Q36352456 | Higher prevalence of proximal colon polyps and villous histology in African-Americans undergoing colonoscopy at a single equal access center |
| Q41848184 | Hirschsprung disease of the colon, a vaginal mass and medullary thyroid cancer - a RET oncogene driven problem |
| Q55251223 | Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. |
| Q36666622 | Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer |
| Q52725074 | How does the tumor microenvironment play a role in hepatobiliary tumors? |
| Q60922826 | How many lymph nodes are enough?-defining the extent of lymph node dissection in stage I-III gastric cancer using the National Cancer Database |
| Q42094716 | How to overcome resistance to therapy? |
| Q112713787 | Hsa_circ_NOTCH3 regulates ZNF146 through sponge adsorption of miR-875-5p to promote tumorigenesis of hepatocellular carcinoma |
| Q102155268 | Huge solid pseudopapillary tumor of the pancreas 'Frantz tumor': a case report |
| Q38510254 | Human papillomavirus tumor infection in esophageal squamous cell carcinoma. |
| Q64882814 | Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. |
| Q33947995 | Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. |
| Q39451631 | Hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant chemotherapy as prophylaxis of peritoneal carcinosis from advanced gastric cancer-effects on overall and disease free survival. |
| Q36582197 | Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role? |
| Q60922809 | Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy |
| Q112287626 | Identification and validation of ferroptosis-associated gene-based on immune score as prognosis markers for hepatocellular carcinoma patients |
| Q112284231 | Identification and validation of xenobiotic metabolism-associated prognostic signature based on five genes to evaluate immune microenvironment in colon cancer |
| Q112292876 | Identification of G-protein signaling modulator 2 as a diagnostic and prognostic biomarker of pancreatic adenocarcinoma: an exploration of its regulatory mechanisms |
| Q112641322 | Identification of a 3-gene signature for predicting the prognosis of stage II colon cancer based on microsatellite status |
| Q112281222 | Identification of a glycolysis-related gene signature for predicting pancreatic cancer survival |
| Q112292873 | Identification of gene biomarkers and immune cell infiltration characteristics in rectal cancer |
| Q112295177 | Identification of gene signatures and potential therapeutic targets for acquired chemotherapy resistance in gastric cancer patients |
| Q112642650 | Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma |
| Q112290185 | Identification of hub genes and functional modules in colon adenocarcinoma based on public databases by bioinformatics analysis |
| Q112284234 | Identification of methyltransferase-like protein 11B as a new prognostic biomarker for colorectal cancer through an analysis of The Cancer Genome Atlas |
| Q90643852 | Identification of potential biomarkers and pathways in ulcerative colitis with combined public mRNA and miRNA expression microarray data analysis |
| Q112287376 | Identification of potential core genes in gastric cancer using bioinformatics analysis |
| Q112277951 | Identification of potential prognostic biomarkers for hepatocellular carcinoma |
| Q112277948 | Identification of the key genes controlling stomach adenocarcinoma stem cell characteristics via an analysis of stemness indices |
| Q42318810 | Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients |
| Q38027525 | Imaging of pancreatic cancer: An overview |
| Q26799450 | Imaging preoperatively for pancreatic adenocarcinoma |
| Q128461027 | Immune checkpoint blockade induced sarcoid-like reaction mimicking progression of disease in a patient with microsatellite instable colorectal cancer: case report and review of the literature |
| Q55255694 | Immune checkpoint inhibitors in gastrointestinal malignancies. |
| Q89579744 | Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy |
| Q26749015 | Immune targeting of cancer stem cells in gastrointestinal oncology |
| Q36162498 | Immunohistochemical features of the gastrointestinal tract tumors |
| Q36936952 | Immunohistochemistry and scoring of Ki-67 proliferative index and p53 expression in gastric B cell lymphoma from Northern African population: a pilot study |
| Q52346985 | Immunomodulation in hepatocellular cancer. |
| Q26781038 | Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations |
| Q55333223 | Immunotherapy in colorectal cancer: for the select few or all? |
| Q39453597 | Immunotherapy in gastrointestinal cancers |
| Q55073226 | Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. |
| Q94602732 | Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers |
| Q36352437 | Impact of age and comorbidity on survival in colorectal cancer |
| Q36582556 | Impact of cytolysis following transarterial chemoembolization for hepatocellular carcinoma |
| Q90346338 | Impact of delaying surgery after chemoradiation in rectal cancer: outcomes from a tertiary cancer centre in India |
| Q99580456 | Impact of examined lymph node count on prognosis in patients with lymph node-negative pancreatic body/tail ductal adenocarcinoma |
| Q99580460 | Impact of immunotherapy use in patients with stage IV pancreatic carcinoma |
| Q58806082 | Impact of intensity modulated radiation therapy on survival in anal cancer |
| Q36666606 | Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy |
| Q94602710 | Impact of radiotherapy duration on overall survival in squamous cell carcinoma of the anus |
| Q54965039 | Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. |
| Q47394363 | Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery |
| Q26772279 | Impact of somatic mutations on patterns of metastasis in colorectal cancer |
| Q26768302 | Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion |
| Q38398877 | Impact of the immune system and immunotherapy in colorectal cancer |
| Q37522219 | Impact of treatment modality and number of lesions on recurrence and survival outcomes after treatment of colorectal cancer liver metastases |
| Q26772272 | Implications of mismatch repair-deficient status on management of early stage colorectal cancer |
| Q37525324 | Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review |
| Q34484312 | Incidence and prognostic impact of high-risk HPV tumor infection in cervical esophageal carcinoma |
| Q92716602 | Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic cancer resection |
| Q64094378 | Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients |
| Q36062584 | Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation |
| Q36062615 | Increased risk of death due to heart disease after radiotherapy for esophageal cancer |
| Q35065542 | Increasing Disparity in Colorectal Cancer Incidence and Mortality Among African Americans and Whites: A State's Experience. |
| Q36097235 | Increasing incidence in liver cancer in Canada, 1972-2006: Age-period-cohort analysis |
| Q41598598 | Individualized 4-dimensional computed tomography proton treatment for pancreatic tumors |
| Q99580594 | Indolent T cell lymphoproliferative disorder of the gastrointestinal tract: an uncommon case with lymph node involvement and the classic Hodgkin's lymphoma |
| Q37677512 | Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy |
| Q64094476 | Inflammatory response and optimalisation of perioperative fluid administration during hyperthermic intraoperative intraperitoneal chemotherapy surgery |
| Q97525395 | Inherited syndromes involving pancreatic neuroendocrine tumors |
| Q36381217 | Inpatient burden of gastrointestinal stromal tumors in the United States |
| Q36097117 | Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. |
| Q36097109 | Insulin-resistant conditions: A favorable milieu for aggressive drug-resistant malignancies |
| Q112297079 | Integrated analysis of competing endogenous RNA in esophageal carcinoma |
| Q112705896 | Integrated omics analysis: the relationship between significantly increased Klebsiella post-hepatectomy and decreased hub-metabolite 3-methyl-2-oxobutanoic acid is associated with induced liver failure |
| Q43090496 | Integrating anti-EGFR therapies in metastatic colorectal cancer |
| Q112717133 | Integrative analysis of TNFRSF6B as a potential therapeutic target for pancreatic cancer |
| Q99580482 | Integrative bioinformatics analysis of prognostic alternative splicing signatures in gastric cancer |
| Q42919204 | Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them? |
| Q35029031 | Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma |
| Q64094487 | Intensive care for patients with gastric cancers: outcome and survival prognostic factors |
| Q92645713 | Interleukin-6 as a biomarker in patients with hepatobiliary cancers |
| Q92716624 | Interleukin-8 associated with chemosensitivity and poor chemotherapeutic response to gastric cancer |
| Q38272994 | Intestinal metaplasia and anastomotic recurrence of gastric carcinoma |
| Q97525338 | Intracorporeal anastomosis versus extracorporeal anastomosis for minimally invasive colectomy |
| Q37285974 | Intrapancreatic accessory spleen presenting as a pancreatic mass. |
| Q38856606 | Intrapancreatic accessory spleen: utilization of fine needle aspiration for diagnosis of a potential mimic of a pancreatic neoplasm |
| Q99580447 | Investigating disparities: the effect of social environment on pancreatic cancer survival in metastatic patients |
| Q37525354 | Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma |
| Q55386854 | Investigation of targetable predictive and prognostic markers in gallbladder carcinoma. |
| Q61804241 | Investigation of the changes in the expression levels of MOZ gene in colorectal cancer tissues |
| Q37677529 | Investigation of the human H3.3B (H3F3B) gene expression as a novel marker in patients with colorectal cancer |
| Q39640786 | Irreversible electroporation of locally advanced pancreatic neck/body adenocarcinoma |
| Q36381231 | Is Endoscopic Ultrasound (EUS) necessary in the pre-therapeutic assessment of Barrett's esophagus with early neoplasia? |
| Q36937023 | Is distance to chemotherapy an obstacle to adjuvant care among the N.C. Medicaid-enrolled colon cancer patients? |
| Q36936979 | Is early response by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer? |
| Q36937018 | Is exposure to Agent Orange a risk factor for hepatocellular cancer?-A single-center retrospective study in the U.S. veteran population |
| Q92716586 | Is hepatic resection better than transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis? |
| Q28073673 | Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? |
| Q92716576 | Is metastasectomy a worthy option?-the role of surgery in metastatic colon cancer to liver and lungs |
| Q90346387 | Is my life going to change?-a review of quality of life after rectal resection |
| Q92645732 | Is postoperative ambulation a component or a marker of enhanced recovery after surgery? |
| Q38915858 | Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. |
| Q58806088 | Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? |
| Q64094465 | Is there difference between anastomotic site and remnant stump carcinoma in gastric stump cancers?-a single institute analysis of 90 patients |
| Q94602753 | Jejunostomy at the time of esophagectomy is associated with improved short-term perioperative outcomes: analysis of the NSQIP database |
| Q95358395 | Joseph Chao: good research is the search for the truth! |
| Q33948020 | KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas |
| Q36097103 | KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy |
| Q90041919 | KRAS, NRAS and BRAF analysis of ampullary adenocarcinoma classified using CK7, CK20, MUC1 and MUC2 |
| Q36936986 | Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience |
| Q60922824 | Krukenberg tumours from gastrointestinal cancers-analysis from a tertiary care centre in India |
| Q26799434 | Laparoscopic distal pancreatectomy for adenocarcinoma: safe and reasonable? |
| Q37522232 | Laparoscopic rectal resection versus open rectal resection with minilaparotomy for invasive rectal cancer |
| Q36097210 | Large cell neuroendocrine carcinoma of the colon: A rare and aggressive tumor |
| Q60922836 | Large database utilization in health outcomes research in pancreatic cancer: an update |
| Q30395541 | Leptomeningeal metastasis as initial manifestation of signet ring colorectal adenocarcinoma: a case report with review of literature |
| Q37525276 | Less than 12 lymph nodes in the surgical specimen after neoadjuvant chemo-radiotherapy: an indicator of tumor regression in locally advanced rectal cancer? |
| Q90346406 | Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma |
| Q43123842 | Liver regeneration following repeat SBRT. |
| Q36062607 | Liver resection for metastatic colorectal leiomyosarcoma: a single center experience. |
| Q97525428 | Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors |
| Q35419309 | Liver-directed conversion therapy in metastatic colon cancer. |
| Q38256165 | Liver-directed therapies in metastatic colorectal cancer |
| Q90346378 | Liver-first approach to stage IV colon cancer with synchronous isolated liver metastases |
| Q35419395 | Local excision for early rectal cancer: transanal endoscopic microsurgery and beyond |
| Q64094440 | Local excision for patients with stage I anal canal squamous cell carcinoma can be curative |
| Q38686790 | Locoregional and systemic therapy for hepatocellular carcinoma |
| Q33593193 | Long term responders to palliative chemotherapy for advanced biliary tract cancer. |
| Q64094429 | Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC) |
| Q45811589 | Long-term oncologic outcomes of stent as a bridge to surgery versus emergency surgery in malignant left side colonic obstructions: a meta-analysis. |
| Q90643901 | Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma |
| Q41894890 | Long-term survival in an advanced gastric cancer patient treated with cetuximab in association with FOLFIRI: a case report |
| Q90643858 | Loss of ferrochelatase is protective against colon cancer cells: ferrochelatase a possible regulator of the long noncoding RNA H19 |
| Q60922865 | Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy |
| Q35029051 | Low bone mineral density linked to colorectal adenomas: a cross-sectional study of a racially diverse population |
| Q61804233 | Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes |
| Q42143802 | Low prevalence of invasive adenocarcinoma and occult cancer on esophageal resection for Barrett's esophagus with high-grade dysplasia: Evidence for conservative management |
| Q42238039 | Low risk of prevalent submucosal invasive cancer among patients undergoing esophagectomy for treatment of Barrett's esophagus with high grade dysplasia |
| Q47159110 | Low-tie IMA and selective D3 lymph node sampling in laparoscopic rectal resection for carcinoma rectum: comparison of surgical and oncological outcomes with the open technique |
| Q61804237 | Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance |
| Q36381240 | Lymph node count in colorectal cancer - do we have the final answer? |
| Q94602725 | Magnetic resonance imaging for preoperative staging of pancreatic cancer based on the 8th edition of AJCC guidelines |
| Q92716670 | Making sense of adjuvant chemotherapy in colorectal cancer |
| Q92716640 | Malignant gastrointestinal neuroectodermal tumor, presenting as a second malignancy after gastric adenocarcinoma: a case report and literature review |
| Q50300036 | Malignant liver tumors: current and emerging therapies 3rd edition, Pierre-Alain Clavien, editor. |
| Q39080594 | Malignant transformation of biliary adenofibroma: a rare biliary cystic tumor. |
| Q92716698 | Management of anastomotic leakage after rectal surgery: a review article |
| Q95358404 | Management of foregut malignancies and hepatobiliary tract and pancreas malignancies |
| Q36097278 | Management of gastrointestinal carcinoid tumours - 10 years experience at a district general hospital |
| Q36936975 | Management of high-output chylous ascites after D2-lymphadenectomy in patients with gastric cancer: a multi-center study |
| Q47132827 | Management of liver metastases from gastrointestinal stromal tumors: where do we stand? |
| Q54959817 | Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. |
| Q97525305 | Management of malignant colonic polyps |
| Q35029056 | Management of oligometastatic rectal cancer: is liver first? |
| Q30278871 | Management of periampullary adenocarcinoma by pancreaticoduodenectomy at a regional teaching hospital |
| Q36097091 | Management of stage II/III rectal cancer |
| Q26749018 | Management of the right hepatic artery in pancreaticoduodenectomy: a systematic review |
| Q92716713 | Managing elderly with colorectal cancer |
| Q90346478 | Managing treatment-related uncertainties in proton beam radiotherapy for gastrointestinal cancers |
| Q24598640 | Markers of resistance to anti-EGFR therapy in colorectal cancer |
| Q41824462 | Masquerade without a mass: an unusual cause of severe acute pancreatitis |
| Q38027520 | Massive upper gastrointestinal hemorrhage due to adenosquamous carcinoma of the pancreas: Case report and literature review. |
| Q64094389 | Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma |
| Q92486877 | Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors |
| Q36666220 | Merkel cell carcinoma of unknown primary with lymph node and mesenteric metastasis involving the pancreas and duodenum |
| Q84587973 | Message from the Editor-in-Chief |
| Q37285953 | Metachronous pancreatic metastasis of an ovarian serous papillary adenocarcinoma after 8 years |
| Q36666639 | Metastatic colon cancer from extrahepatic cholangiocarcinoma presenting as painless jaundice: case report and literature review |
| Q26749022 | Metastatic colorectal cancer presenting with bone marrow metastasis: a case series and review of literature |
| Q92486914 | MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma |
| Q36097056 | MicroRNAs and esophageal cancer |
| Q42318809 | Minimally invasive Ivor-Lewis esophagectomy for esophageal cancer with right aortic arch |
| Q97525329 | Minimally invasive complete mesocolic excision and central vascular ligation (CME/CVL) for right colon cancer |
| Q90346394 | Minimally invasive surgery for appendiceal intussusception caused by mucocele of the appendix: case report and review of the literature |
| Q97525372 | Minimally invasive surgery in the geriatric patient with colon cancer |
| Q35057393 | Mismatch repair protein expression in colorectal cancer |
| Q94602763 | Modified endoscopic full-thickness resection of gastric stromal tumor originating from the muscularis propria layer |
| Q33895591 | Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature |
| Q36162528 | Molecular pathology of pancreatic neuroendocrine tumors |
| Q36666663 | Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy |
| Q92486872 | Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets |
| Q28072275 | Molecular profiling of biliary tract cancer: a target rich disease |
| Q37525272 | Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. |
| Q26749012 | Molecular testing to optimize therapeutic decision making in advanced colorectal cancer |
| Q64905889 | Morbidity and mortality of synchronous hepatectomy with cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). |
| Q27024637 | Motion management in gastrointestinal cancers |
| Q92645751 | Mucinous adenocarcinoma arising from chronic perianal fistula-a multidisciplinary approach |
| Q36381198 | Mucinous adenocarcinoma of the appendix presenting as intussusception in 27 year old female |
| Q33948014 | Mucinous adenocarcinoma of the rectum: a poor candidate for neo-adjuvant chemoradiation? |
| Q102155265 | Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer |
| Q35028984 | Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres |
| Q61804231 | Multimodality management of incidentally detected gall bladder cancer: long term results from a tertiary care cancer centre |
| Q36666649 | Multimodality therapy of rectal gastrointestinal stromal tumors in the era of imatinib-an Indian series |
| Q42318807 | Multiple angiodysplasia diagnosed by capsule endoscopy |
| Q90041942 | Multiple primary malignancies in patients with anal squamous cell carcinoma |
| Q36937006 | Multivisceral resections for rectal cancers: short-term oncological and clinical outcomes from a tertiary-care center in India. |
| Q41877169 | Muscular metastasis from gastric cancer. |
| Q36936956 | Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways |
| Q41598555 | Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency or microsatellite instability in patients with colorectal cancers |
| Q37131675 | Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma. |
| Q37285948 | Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma |
| Q36097175 | Nanovector-based therapies in advanced pancreatic cancer |
| Q64094468 | Natural killer NKG2A and NKG2D in patients with colorectal cancer |
| Q58806064 | Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer |
| Q36666618 | Neoadjuvant chemoradiation followed by orthotopic liver transplantation in cholangiocarcinomas: the emory experience |
| Q40073167 | Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma |
| Q37285962 | Neoadjuvant hyperfractionated-accelerated radiotherapy with concomitant chemotherapy in esophageal cancer: phase II study |
| Q37131713 | Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib. |
| Q92486874 | Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis |
| Q26781043 | Neoadjuvant therapy for gastric cancer: current evidence and future directions |
| Q26799428 | Neoadjuvant therapy for localized pancreatic cancer: guiding principles |
| Q102155232 | Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review |
| Q33895552 | Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation |
| Q36047844 | Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry |
| Q128542470 | Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis |
| Q102155228 | New insights into benefits of combination treatment with yttrium-90 and gemcitabine in patients with intrahepatic cholangiocarcinoma |
| Q42919208 | New possibilities and potential benefits for local control in locally recurrent pancreatic cancer |
| Q26772277 | New therapeutic strategies for BRAF mutant colorectal cancers |
| Q42318808 | Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancer |
| Q99580406 | Non-anaemic iron deficiency should be investigated with the same priority as iron deficiency anaemia in fast track colorectal clinics-retrospective cohort study |
| Q38398883 | Non-operative therapies for colorectal liver metastases |
| Q36666234 | Non-pancreatic retroperitoneal mucinous neoplasms and a discussion of the differential diagnosis |
| Q55618410 | Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis. |
| Q26799425 | Novel adjuvant therapies for pancreatic adenocarcinoma |
| Q33820792 | Novel radiation techniques for rectal cancer |
| Q61804223 | Novel use of proton beam therapy for neoadjuvant treatment of radiation-associated squamous cell carcinoma of the esophagus |
| Q35028989 | Numb chin syndrome secondary to leptomeningeal carcinomatosis from gastric adenocarcinoma |
| Q90346411 | Obesity and younger versus older onset colorectal cancer in the United States, 1998-2017 |
| Q36097132 | Obesity, insulin and chemoresistance in colon cancer |
| Q92486911 | Open surgical treatment for esophageal cancer: transhiatal vs. transthoracic, does it really matter? |
| Q39289723 | Operative microwave ablation for hepatocellular carcinoma: a single center retrospective review of 219 patients. |
| Q35419468 | Optimal interval of surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: population level evidence in addition to controlled trial |
| Q64966659 | Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis. |
| Q42359710 | Optimizing the management of hepatobiliary neoplasms: a multidisciplinary and molecular challenge |
| Q37525339 | Osteonecrosis of the jaw associated with ziv-aflibercept |
| Q58806095 | Outcome and factors associated with aborted cytoreduction for peritoneal carcinomatosis |
| Q64094461 | Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies |
| Q36936965 | Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study |
| Q37677569 | Outcome of young patients with rectal adenocarcinoma. |
| Q41598560 | Outcomes and complications of radiation therapy in patients with familial adenomatous polyposis |
| Q61804229 | Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors—a single-institution experience |
| Q90042003 | Outcomes associated with robotic approach to pancreatic resections |
| Q37131697 | Outcomes in patients with brain metastasis from esophageal carcinoma |
| Q47155379 | Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy |
| Q64094379 | Outcomes of endoscopic submucosal dissection in esophageal adenocarcinoma staged T1bN0 by endoscopic ultrasound in non-surgical patients |
| Q58806059 | Outcomes of patients in the national cancer database treated non-surgically for localized rectal cancer |
| Q33948026 | Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs |
| Q34484282 | Outcomes of rectal cancer with liver oligometastases |
| Q36062611 | Outcomes of resected pancreatic cancer in patients age ≥70. |
| Q33895603 | Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis |
| Q37723273 | Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer |
| Q58806060 | Overexpression of SSH1 in gastric adenocarcinoma and its correlation with clinicopathological features |
| Q55605577 | Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy. |
| Q47233779 | Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer |
| Q26799422 | Pain management of pancreatic head adenocarcinomas that are unresectable: celiac plexus neurolysis and splanchnicectomy |
| Q55690582 | Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer. |
| Q26768306 | Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer? |
| Q36062629 | Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancer |
| Q41894893 | Palliative radiation therapy for primary gastric melanoma |
| Q92716650 | Palliative radiotherapy for hepatobiliary obstruction caused by colorectal metastases |
| Q36582541 | Palliative stenting of the digestive tract: a case series of a single centre |
| Q60922849 | Pancreas cancer, careful improvements and human connections |
| Q41566079 | Pancreas cancer: why bother? |
| Q26799446 | Pancreatic adenocarcinoma pathology: changing "landscape" |
| Q36097184 | Pancreatic cancer: current standards, research updates and future directions |
| Q41931507 | Pancreatic head carcinoma and right hepatic artery: embolization management-A case report |
| Q97525389 | Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication |
| Q47147328 | Pancreatic non-functioning neuroendocrine tumor: a new entity genetically related to Lynch syndrome |
| Q39640756 | Paraneoplastic cutaneous lupus secondary to esophageal squamous cell carcinoma |
| Q36162507 | Pathologic aspects of tumors of gastrointestinal tract in the era of personalized medicine |
| Q99580469 | Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction |
| Q36303649 | Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials |
| Q37131682 | Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome |
| Q36666602 | Patient and caregiver awareness of pancreatic cancer treatments and clinical trials |
| Q41904824 | Patient selection for hepatic resection for metastatic colorectal cancer |
| Q36097160 | Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standard |
| Q92716614 | Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers |
| Q90346335 | Patterns of care and outcomes for adjuvant treatment of pT3N0 rectal cancer using the National Cancer Database |
| Q92486858 | Patterns of care and outcomes of intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for anal cancer |
| Q34484328 | Patterns of failure for stage I ampulla of Vater adenocarcinoma: a single institutional experience |
| Q37131708 | Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious. |
| Q46014292 | Pediatric liver tumors, Series:. |
| Q92716684 | Pelvic exenteration for locally advanced and recurrent rectal cancer-how much more? |
| Q58806071 | Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer |
| Q36666686 | Percutaneous "Y" biliary stent placement in palliative treatment of type 4 malignant hilar stricture |
| Q26772270 | Percutaneous ablation of colorectal lung metastases |
| Q37525334 | Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden |
| Q55265930 | Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. |
| Q92645728 | Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial |
| Q37525286 | Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer |
| Q125947411 | Perineural invasion is a prognostic factor in stage II colorectal cancer but not a treatment indicator for traditional chemotherapy: a retrospective cohort study |
| Q41900956 | Perioperative management of hepatic resection |
| Q36666653 | Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy |
| Q38461953 | Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). |
| Q92486923 | Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV |
| Q39453553 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies |
| Q28066268 | Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? |
| Q36097060 | Personalized therapy for pancreatic cancer: Myth or reality in 2010? |
| Q37525368 | Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. |
| Q36666645 | Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma |
| Q92645674 | Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer |
| Q90643918 | Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin |
| Q90346365 | Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma |
| Q60922860 | Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience |
| Q47139613 | Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer |
| Q64094481 | Population-based assessment of the performance of sigmoidoscopy in the detection of colorectal cancer: implications for future screening recommendations |
| Q36936947 | Positron emission tomography for initial staging of esophageal cancer among medicare beneficiaries |
| Q36937011 | Post operative stereotactic radiosurgery for positive or close margins after preoperative chemoradiation and surgery for rectal cancer |
| Q47106223 | Post-operative radiotherapy is associated with improved survival in esophageal cancer with positive surgical margins |
| Q37723265 | Posterior reversible leukoencephalopathy syndrome secondary to hepatic transarterial chemoembolization with doxorubicin drug eluting beads |
| Q34962091 | Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy. |
| Q38027530 | Postoperative management after hepatic resection |
| Q128525944 | Postoperative superior anastomotic leakage classification and treatment strategy for postoperative esophagogastric junction cancer |
| Q37677552 | Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis |
| Q92645694 | Pre-operative percutaneous endoscopic gastrostomy tube placement does not increase post-operative complications or mortality in oesophageal cancer |
| Q35029046 | Predicting complete response: is there a role for non-operative management of rectal cancer? |
| Q42076423 | Predicting, preventing, treating and understanding radiation nephropathy |
| Q112287621 | Prediction and prognostic significance of ALOX12B and PACSIN1 expression in gastric cancer by genome-wide RNA expression and methylation analysis |
| Q64880178 | Prediction of colorectal cancer risk among adults in a lower middle-income country. |
| Q39453559 | Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment |
| Q41970461 | Predictive or non-predictive, prognostic or non-prognostic: Dilemmas generated through small retrospective studies |
| Q44749754 | Predictors of intermediate-term survival with destination locoregional therapy of hepatocellular cancer in patients either ineligible or unwilling for liver transplantation |
| Q94602750 | Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategies-a single institution experience |
| Q54941136 | Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country. |
| Q92716655 | Preface to the current status of colorectal cancer surgery |
| Q97525295 | Preface to the current strategies in colon cancer management |
| Q89579754 | Preferential use of imaging modalities in staging newly diagnosed rectal cancer: a survey of US radiation oncologists |
| Q47139838 | Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography |
| Q26768400 | Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy |
| Q37285970 | Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer |
| Q102155259 | Preoperative computed tomography-assessed skeletal muscle index is a novel prognostic factor in patients with hepatocellular carcinoma following hepatectomy: a meta-analysis |
| Q92716581 | Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma |
| Q36097250 | Preoperative imaging for hepatic resection of colorectal cancer metastasis. |
| Q55082575 | Preoperative survival calculator for resectable hepatocellular carcinoma. |
| Q41836511 | Preoperative therapies for resectable and borderline resectable pancreatic cancer |
| Q47112804 | Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver |
| Q37525319 | Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres |
| Q41960600 | Prevalence of adenocarcinoma at esophagectomy for Barrett's esophagus with high grade dysplasia |
| Q33895573 | Primary and acquired resistance to biologic therapies in gastrointestinal cancers |
| Q42145786 | Primary hepatic anaplastic large cell ki-1 lymphoma and celiac disease: a casual association? |
| Q42038893 | Primary mesenteric liposarcoma: An unusual presentation of a rare condition |
| Q41598507 | Primary pancreatic lymphoma: what we need to know. |
| Q64945921 | Primary squamous cell carcinoma of the peristomal skin of gastrostomy in a transplant patient: a first case report. |
| Q47101091 | Probable paclitaxel-induced pancreatitis: uncommon case report and literature review |
| Q99580656 | Professor Yanghee Woo: globalization of surgical innovation for stomach cancer treatment-a long but exciting road |
| Q36352432 | Proficiency of DNA repair genes and microsatellite instability in operated colorectal cancer patients with clinical suspicion of lynch syndrome |
| Q112287619 | Prognostic and immune infiltrates for the Chromobox (CBX) protein family in human pancreatic adenocarcinoma |
| Q55024717 | Prognostic factors and hazard ratios in colorectal cancer patients over 80 years of age: a retrospective, 20-year, single institution review. |
| Q47141291 | Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study |
| Q37525296 | Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma |
| Q102155233 | Prognostic implications of mucinous histology in stage III colon cancer with the receipt of adjuvant chemotherapy |
| Q60922846 | Prognostic importance of lymph node ratio after resection of ampullary carcinomas |
| Q37677538 | Prognostic influence of histopathological regression patterns in rectal adenocarcinoma receiving neoadjuvant therapy. |
| Q47128634 | Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base |
| Q102155258 | Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation |
| Q36666680 | Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy |
| Q112584571 | Prognostic value and association of sarcopenic obesity and systemic inflammatory indexes in patients with hepatocellular carcinoma following hepatectomy and the establishment of novel predictive nomograms |
| Q36303653 | Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. |
| Q61804254 | Prognostic value of multiple cytokine analysis in colorectal cancer: a systematic review |
| Q54979803 | Prolonged survival of metastatic hepatocellular carcinoma: a case report. |
| Q64094384 | Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma |
| Q39453620 | Promising therapeutics of gastrointestinal cancers in clinical trials |
| Q39674083 | Prophylactic hyperthermic intraperitoneal chemotherapy can be considered in the management of advanced gastric cancer |
| Q90346457 | Proton beam radiotherapy for anal and rectal cancers |
| Q90346450 | Proton beam radiotherapy for pancreas cancer |
| Q90346464 | Proton beam re-irradiation for gastrointestinal malignancies: a systematic review |
| Q41598639 | Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma |
| Q90042018 | Proton beam therapy for gastrointestinal cancers: past, present, and future |
| Q90346442 | Proton beam therapy for liver cancers |
| Q90643944 | Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation |
| Q42002060 | Proton therapy may allow for comprehensive elective nodal coverage for patients receiving neoadjuvant radiotherapy for localized pancreatic head cancers |
| Q41894910 | Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer |
| Q27027549 | Psychosocial issues in colorectal cancer survivorship: the top ten questions patients may not be asking |
| Q35419454 | Pulmonary metastases in pancreatic cancer, is there a survival influence? |
| Q38795369 | Pyloric gland adenoma of gallbladder-reports of two cases and a brief review of literature |
| Q26825504 | Quality of life and hepatocellular carcinoma |
| Q90643939 | Quality of life as a fundamental outcome after curative intent gastrectomy for adenocarcinoma: lessons learned from patients |
| Q34484260 | Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial |
| Q28074175 | RAS and BRAF in metastatic colorectal cancer management |
| Q41864780 | RE: Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroen |
| Q61804256 | Racial and gender disparities in the incidence of anal cancer: analysis of the Nationwide Inpatient Sample (NIS) |
| Q64094369 | Racial disparities in the incidence of colon cancer in patients with inflammatory bowel disease |
| Q55051950 | Racial/ethnic disparities in gallbladder cancer receipt of treatments. |
| Q90346484 | Radiation biology considerations of proton therapy for gastrointestinal cancers |
| Q53276116 | Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base. |
| Q47098450 | Radiation generates an abscopal response and complete resolution of metastatic squamous cell carcinoma of the anal canal: a case report |
| Q41598658 | Radiation induced gastroparesis-case report and literature review. |
| Q33593244 | Radiation therapy for hepatobiliary malignancies |
| Q92716703 | Radiation therapy for rectal cancer |
| Q38027516 | Radiation therapy in the postoperative management of esophageal cancer |
| Q90346421 | Radiation-induced hepatitis masquerading as metastatic disease: the importance of correlating diagnostic imaging with treatment planning |
| Q33820777 | Radioembolization of hepatic tumors |
| Q37525291 | Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study |
| Q36062588 | Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma |
| Q37525344 | Radiographic and endoscopic regression of metastatic gastric cancer to the colon in the setting of 5-aminosalicylic acid use. |
| Q35419356 | Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience |
| Q36381206 | Radiotherapy versus stenting in treating malignant dysphagia |
| Q94602735 | Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres |
| Q42095635 | Rapid onset of myelodysplastic syndrome after treatment for anal cancer: A case report |
| Q33948000 | Rapidly progressive subcutaneous metastases from gallbladder cancer: insight into a rare presentation in gastrointestinal malignancies |
| Q99580606 | Rare postoperative hemorrhage after robotic-assisted pancreatoduodenectomy for pancreatic head cancer: a case report |
| Q37285956 | Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions |
| Q99580424 | Real world aspects of palliative trifluridine plus tiperacil (TAS-102) in refractory metastatic colorectal cancer |
| Q36792353 | Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastasis |
| Q90041930 | Reclassification of lesions in biopsies by fine-needle aspiration of pancreas and biliary tree using Papanicolaou classification |
| Q36666673 | Recognizing the distinct cytomorphologic features of solid pseudopapillary neoplasm of the pancreas |
| Q55092339 | Rectal and anal canal neuroendocrine tumours. |
| Q90643884 | Rectal cancer in the young: analysis of contributing factors and surgical outcomes |
| Q102155239 | Rectal cancer in young patients: incidence and outcome disparities |
| Q37677561 | Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system. |
| Q41932203 | Rectal cancer: a truly multidisciplinary challenge |
| Q41866787 | Rectal cancer: do protons have prospects? |
| Q55690221 | Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. |
| Q42761076 | Regorafenib could cause sinusoidal obstruction syndrome |
| Q41960977 | Regorafenib-induced transverse myelopathy after stereotactic body radiation therapy. |
| Q30279258 | Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report |
| Q94602728 | Relationship between IL-10 and PD-L1 in esophageal carcinoma tissues and IL-10 down-regulates PD-L1 expression via Met signaling pathway |
| Q33948042 | Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma |
| Q26768299 | Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes |
| Q92486921 | Report of three cases of gastric choriocarcinomas-an emphasis on morphologic changes in the non-affected gastric mucosa |
| Q41852206 | Resection of non-hepatic colorectal cancer metastasis |
| Q36937037 | Restaging after neoadjuvant chemoradiation in rectal cancers: is histology the key in patient selection? |
| Q37525377 | Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: a pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven |
| Q86634413 | Retraction: The early diagnosis of pancreatic cancer and diabetes: what's the relationship? |
| Q42206450 | Retroperitoneal nodular fasciitis: a benign etiology on the differential diagnosis of malignant gastric outlet obstruction |
| Q90041914 | Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX |
| Q58806069 | Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma |
| Q60922820 | Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q112290645 | Risk characteristics with seven epithelial-mesenchymal transition-related genes are used to predict the prognosis of patients with hepatocellular carcinoma |
| Q34962022 | Robotic assisted Ivor Lewis esophagectomy in the elderly patient |
| Q26799438 | Robotic pancreaticoduodenectomy for pancreatic adenocarcinoma: role in 2014 and beyond |
| Q92716694 | Robotic surgery in colorectal cancer: the way forward or a passing fad |
| Q36162524 | Role of cytopathology in the diagnosis and management of gastrointestinal tract cancers |
| Q36062637 | Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis |
| Q58806085 | Role of lymph node ratio in selection of adjuvant treatment (chemotherapy chemoradiation) in patients with resected gastric cancer |
| Q94602760 | Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm |
| Q35158527 | Safety and efficacy of esophageal stents preceding or during neoadjuvant chemotherapy for esophageal cancer: a systematic review and meta-analysis |
| Q92486880 | Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience |
| Q55001833 | Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. |
| Q42748133 | Safety implications of oesophageal stents used for the palliation of dysphagia in patients undergoing neoadjuvant therapy for oesophageal malignancy |
| Q42748142 | Safety implications of oesophageal stents used for the palliation of dysphagia in patients undergoing neoadjuvant therapy for oesophageal malignancy-authors' reply |
| Q47134709 | Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus |
| Q38924516 | Sarcoid reaction: a rare occurrence associated to colon adenocarcinoma (case report and literature review). |
| Q38665539 | Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: a multi-institutional analysis. |
| Q112284239 | Screening of a novel autophagy-related prognostic signature and therapeutic targets in hepatocellular carcinoma |
| Q112290184 | Screening potential prognostic biomarkers for portal vein emboli in patients with hepatocellular carcinoma |
| Q34484299 | Second-line systemic treatment for advanced cholangiocarcinoma |
| Q55223567 | Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. |
| Q36937031 | Selective extra levator versus conventional abdomino perineal resection: experience from a tertiary-care center |
| Q45922623 | Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. |
| Q33593257 | Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma |
| Q41370462 | Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy |
| Q41370754 | Self-expanding metal stents for preoperative biliary drainage in patients receiving neoadjuvant therapy for pancreatic cancer |
| Q35158530 | Sentinel lymph node in oesophageal cancer-a systematic review and meta-analysis |
| Q39453577 | Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma |
| Q47161713 | Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma |
| Q64094421 | Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided? |
| Q37723248 | Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials |
| Q40072841 | Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy |
| Q36666658 | Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer |
| Q64094411 | Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases |
| Q90041926 | Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital |
| Q55534659 | Single nucleotide polymorphism rs4648298 in miRNAs hsa-miR21 and hsa-miR590 binding site of COX gene is a strong colorectal cancer determinant. |
| Q36097070 | Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal and pelvic cancers: short-term local control, metabolic response, and toxicity |
| Q36352445 | Sister Mary Joseph's nodule as initial presentation of carcinoma caecum-case report and literature review |
| Q112287623 | Six mutator-derived lncRNA signature of genome instability for predicting the clinical outcome of colon cancer |
| Q42238050 | Skin metastases from esophageal and esophagogastric junction cancer |
| Q36936934 | Small caliber covered self-expanding metal stents in the management of malignant dysphagia |
| Q36792359 | Small cell carcinoma of the anus in the setting of prior squamous dysplasia and carcinoma in situ |
| Q36582570 | Socioeconomic status, p53 abnormalities, and colorectal cancer |
| Q28393971 | Soft tissue tumors of the anorectum: rare, complex and misunderstood |
| Q40073437 | Solitary gastric metastasis from primary lung adenocarcinoma: a rare site of extra-thoracic metastatic disease |
| Q36097154 | Splenectomy ameliorates hematologic toxicity of hyperthermic intraperitoneal chemotherapy |
| Q41598605 | Splenectomy is an independent risk factor for poorer perioperative outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an analysis of 936 procedures |
| Q36097165 | Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| Q38965174 | Spontaneous tumor lysis syndrome in a patient with cholangiocarcinoma |
| Q36097225 | Squamous cell carcinoma of the rectum, primary or metastatic? |
| Q60922838 | Stage II-III colon cancer: a comparison of survival calculators |
| Q61804230 | Staging and survival of colorectal cancer (CRC) in octogenarians: Nationwide Study of US Veterans |
| Q38340518 | State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment |
| Q92716708 | Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer |
| Q37015712 | Status of targeted therapies in the adjuvant treatment of colon cancer |
| Q97525321 | Stenting versus surgery in obstructed malignant colorectal cancer-a review of short and long-term results |
| Q58806078 | Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma |
| Q27008308 | Stereotactic body radiation therapy for liver metastases |
| Q90041948 | Stereotactic body radiation therapy in primary hepatocellular carcinoma: current status and future directions |
| Q47146583 | Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival |
| Q26747145 | Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist |
| Q64094436 | Stomach-partitioning gastrojejunostomy is better than conventional gastrojejunostomy in palliative care of gastric outlet obstruction for gastric or pancreatic cancer: a meta-analysis |
| Q64891069 | Stop hedging your bets: reasons for non-adherence to a tri-modality regimen in the treatment of esophageal cancer in a multidisciplinary setting. |
| Q64932151 | Study of cofilin 1 gene expression in colorectal cancer. |
| Q90643949 | Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion |
| Q37525358 | Successful hepatectomy for metastatic squamous cell carcinoma of the anal canal-a case report |
| Q28078610 | Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? |
| Q28080081 | Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach |
| Q60922831 | Supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with gastric cancer |
| Q36062633 | Surgery for gallbladder cancer in the US: a need for greater lymph node clearance |
| Q37522240 | Surgical and radiation therapy management of recurrent anal melanoma |
| Q97525347 | Surgical management and hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer |
| Q34962070 | Surgical management of gastric cancer: the East vs. West perspective |
| Q46291019 | Surgical management of hepatobiliary and pancreatic disorders, 2nd ed. |
| Q39640966 | Surgical management of hepatocellular carcinoma after Fontan procedure. |
| Q97525421 | Surgical management of pancreatic neuroendocrine liver metastases |
| Q97525411 | Surgical management of primary pancreatic neuroendocrine tumors |
| Q97525355 | Surgical management of recurrent colon cancer |
| Q37525306 | Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX? |
| Q94602722 | Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center |
| Q26768405 | Surgical technology and pharmacology of hyperthermic perioperative chemotherapy |
| Q42153788 | Surgical treatment of colorectal cancer hepatic metastasis |
| Q35419441 | Surveillance for asymptomatic recurrence in resected stage III colon cancer: does it result in a more favorable outcome? |
| Q60922829 | Survey results of US radiation oncology providers' contextual engagement of watch-and-wait beliefs after a complete clinical response to chemoradiation in patients with local rectal cancer |
| Q61804228 | Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience |
| Q46207839 | Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer: a population based analysis |
| Q92486855 | Survival benefits and predictors of use of chemoradiation compared with radiation alone for early stage (T1-T2N0) anal squamous cell carcinoma |
| Q94602739 | Survival benefits of palliative gastrectomy in stage IV gastric cancer: a propensity score matched analysis |
| Q44761183 | Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. |
| Q36097149 | Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity |
| Q92716619 | Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method |
| Q90643865 | Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database |
| Q44817675 | Survivorship after treatment of pancreatic cancer: insights via an Internet-based survivorship care plan tool |
| Q38027524 | Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature |
| Q41810739 | Synchronous resection of colorectal primary and hepatic metastasis |
| Q33895569 | Systematic review and a meta-analysis of hospital and surgeon volume/outcome relationships in colorectal cancer surgery |
| Q26781040 | Systematic review on quality of life outcomes after gastrectomy for gastric carcinoma |
| Q33593213 | Systemic therapy for advanced hepatocellular carcinoma: an update |
| Q33593200 | Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy |
| Q28088453 | Systemic treatment of gastric and esophageal adenocarcinoma in elderly patients |
| Q61804226 | T4N0 colon cancers should be treated like T3N1 disease |
| Q112287381 | TCGA database analysis of the tumor mutation burden and its clinical significance in colon cancer |
| Q36936939 | TNFRSF10C copy number variation is associated with metastatic colorectal cancer. |
| Q60922864 | Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center |
| Q42385734 | Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape |
| Q37015697 | Targeted therapies in colorectal cancer: surgical considerations |
| Q39357003 | Targeted therapies in colorectal cancer: the dos, don'ts, and future directions |
| Q30234532 | Targeted therapy in biliary tract cancers-current limitations and potentials in the future |
| Q94602690 | Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer |
| Q26747140 | Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises |
| Q33820797 | Technical aspects of radiation therapy for anal cancer |
| Q38027529 | Techniques of hepatic resection |
| Q92716608 | Telomerase activity in the differential diagnosis of pancreatic mass |
| Q112295826 | Temporary impairment of renal function in patients with rectal cancer treated with diverting ileostomy |
| Q42353292 | The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice |
| Q64978863 | The accuracy of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as a marker for gastrointestinal malignancies. |
| Q37677558 | The anatomy of the TNM for colon cancer |
| Q102155242 | The anti-tumor effect of miR-539-3p on colon cancer via regulating cell viability, motility, and nude mouse tumorigenicity with CDK14 inhibition |
| Q41464318 | The art and science of radiation therapy for gastrointestinal cancers |
| Q36792350 | The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer |
| Q36162512 | The association between obesity factor and esophageal caner |
| Q34484237 | The association of H. pylori and colorectal adenoma: does it exist in the US Hispanic population? |
| Q90346349 | The association of lymphotoxin-beta receptor with the subsequent diagnosis of incident gastrointestinal cancer: results from the Dallas Heart Study |
| Q92716596 | The clinical significance of simple endoscopic scoring of patients with rectal cancer after concurrent chemoradiotherapy |
| Q36937026 | The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases |
| Q42238114 | The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal |
| Q55153904 | The coming of age: immunotherapy in gastrointestinal malignancies. |
| Q36381237 | The complexity of the count: considerations regarding lymph node evaluation in colorectal carcinoma |
| Q37677535 | The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future? |
| Q47105286 | The correlations between serum amphiregulin and other clinicopathological factors in colorectal cancer |
| Q112691174 | The diagnosis and outcome of Krukenberg tumors |
| Q64965619 | The downstaging approach to irresectable oesophageal and gastric cancer: a single centre experience. |
| Q34450178 | The early diagnosis of pancreatic cancer and diabetes: what's the relationship? |
| Q112280908 | The early predictive effect of low expression of the ITGA4 in colorectal cancer |
| Q112284229 | The effect of PPP2CA expression on the prognosis of patients with hepatocellular carcinoma and its molecular biological characteristics |
| Q64094490 | The effect of intraoperative fluid administration on outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy |
| Q92486869 | The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors |
| Q34234935 | The emerging role of neoadjuvant chemotherapy for rectal cancer |
| Q90346435 | The emerging role of proton therapy for esophagus cancer |
| Q34234956 | The evolution of colorectal cancer genetics-Part 1: from discovery to practice |
| Q34234950 | The evolution of colorectal cancer genetics-Part 2: clinical implications and applications |
| Q112298748 | The expression and prognostic value of GLYATL1 and its potential role in hepatocellular carcinoma |
| Q37677518 | The frequency of histologically confirmed Barrett's esophagus varies by the combination of ethnicity and gender |
| Q38510263 | The functional and prognostic implications of regulatory T cells in colorectal carcinoma |
| Q28078788 | The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond |
| Q57172698 | The gut microbiome and colorectal cancer: a review of bacterial pathogenesis |
| Q64094471 | The impact of BMI extremes on disease-free survival and overall survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| Q92486909 | The impact of the open-access status on journal indices: oncology journals |
| Q58806062 | The incidence of colorectal cancer in patients with previously removed polyp(s)-a cross-sectional study |
| Q102155249 | The incidence, risk factors and predictive nomograms for early death among patients with stage IV gastric cancer: a population-based study |
| Q37723257 | The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. |
| Q34484336 | The localisation of cancer in the sigmoid, rectum or rectosigmoid junction using endoscopy or radiology-What is the most accurate method? |
| Q128461024 | The long-term outcomes and prognostic factors about locally advanced right colon cancer: a retrospective cohort study |
| Q52643531 | The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. |
| Q55717554 | The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer. |
| Q112290181 | The predictive value of RNA binding proteins in colon adenocarcinoma |
| Q37131689 | The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis |
| Q90643928 | The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer |
| Q28069924 | The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 |
| Q41370871 | The quandary of N0 disease after neoadjuvant therapy for rectal cancer |
| Q40072879 | The re-birth of hepatic arterial infusion for colorectal liver metastases |
| Q36381213 | The real face of juvenile polyposis syndrome |
| Q60922857 | The relationship between aspirin use and mortality in colorectal cancer |
| Q36666677 | The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen |
| Q28074145 | The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine? |
| Q36582552 | The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer |
| Q40073074 | The role of Endoscopic Ultrasound (EUS) in the management of patients with pancreatic cancer: now bigger than ever |
| Q34484273 | The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma |
| Q33440012 | The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia |
| Q36097197 | The role of epithelial-mesenchymal transition in pancreatic cancer |
| Q41598579 | The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland |
| Q60922840 | The role of lineage specifiers in pancreatic ductal adenocarcinoma |
| Q42176352 | The role of local excision in invasive adenocarcinoma of the ampulla of Vater |
| Q43136773 | The role of local excision in invasive adenocarcinoma of the ampulla of Vater |
| Q41598613 | The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis. |
| Q36097189 | The role of radiotherapy in management of pancreatic cancer |
| Q65002154 | The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. |
| Q36097240 | The role of taxanes in the management of gastroesphageal cancer |
| Q92645682 | The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients |
| Q37015715 | The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers |
| Q99580578 | The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer |
| Q38225135 | The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far? |
| Q39453628 | The utility of positron emission tomography/computed tomography in target delineation for stereotactic body radiotherapy for liver metastasis from primary gastric cancer: an illustrative case report and literature review |
| Q36097201 | The value of cyst fluid analysis in the pre-operative evaluation of pancreatic cysts |
| Q58806093 | The value of oxaliplatin in the systemic treatment of locally advanced rectal cancer |
| Q61804225 | The value of using fludeoxyglucose positron-emission tomography scan with respect to colorectal abnormalities—a cross-sectional study |
| Q26768408 | Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective |
| Q34234928 | Therapeutic approaches in the management of locally advanced rectal cancer |
| Q42238111 | Thermal tumor ablation therapy for colorectal cancer hepatic metastasis |
| Q36352426 | Thirty days post-operative mortality after surgery for colorectal cancer: a descriptive study |
| Q35419411 | Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab |
| Q92486843 | Timing of surgery following neoadjuvant chemoradiation in rectal cancer: a retrospective analysis from an academic medical center |
| Q41894899 | Total gastrectomy with isoperistaltic jejunal interposition flap for symptomatic management of gastric polyposis from familial adenomatous polyposis |
| Q42056784 | Tracheo-oesophageal fistula after palliative treatment of oesophageal cancer |
| Q26781036 | Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review |
| Q60922852 | Transabdominal ultrasonographic features in the diagnosis of gastrointestinal lymphoma |
| Q92716675 | Transanal total mesorectal excision for rectal cancer: hype or new hope? |
| Q42210757 | Transition of a pancreatic neuroendocrine tumor from ghrelinoma to insulinoma: a case report |
| Q55091182 | Travel distance and use of salvage palliative chemotherapy in patients with metastatic colorectal cancer. |
| Q92486889 | Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study |
| Q90643846 | Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: a multicenter retrospective analysis |
| Q61804242 | Treatment disparities affect outcomes for patients with stage I esophageal cancer: a national cancer data base analysis |
| Q33593225 | Treatment of advanced Gall bladder cancer in the real world-can continuation chemotherapy improve outcomes? |
| Q36381222 | Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience |
| Q37131666 | Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico |
| Q36792376 | Treatment outcome of gastric extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in the Hong Kong Chinese population: a single centre experience |
| Q61804239 | Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis |
| Q97525380 | Treatment sequencing for pancreatic neuroendocrine tumors: daring to challenge the status quo |
| Q57172701 | Trends and disparities in the utilization of hypofractionated neoadjuvant radiation therapy for rectal cancer in the United States |
| Q64094415 | Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014 |
| Q90643933 | Trends of incidence and survival in patients with gastroenteropancreatic signet ring cell carcinoma: an analysis from the Surveillance, Epidemiology, and End Results program |
| Q26772274 | Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases |
| Q42027603 | Tumor exosomes: a novel biomarker? |
| Q55313926 | Tumor location impact in stage II and III colon cancer: epidemiological and outcome evaluation. |
| Q112641317 | Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer |
| Q38965447 | Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. |
| Q47097188 | Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. |
| Q41598524 | Tumor stage in patients operated for rectal cancer: a comparison of the pre-operative MR and the resection specimen, with specific attention to the effect of neo-adjuvant radiotherapy |
| Q64094447 | Typical carcinoids, goblet cell carcinoids, mixed adenoneuroendocrine carcinomas, neuroendocrine carcinomas and adenocarcinomas of the appendix: a comparative analysis of survival profile and predictors |
| Q41779437 | Uncommon conditions in surgical oncology: acute abdomen caused by ileocolic intussusception |
| Q89579806 | Uncovering the barriers to undergoing screening among first degree relatives of colorectal cancer patients: a review of qualitative literature |
| Q112290180 | Underlying mechanism of sorafenib resistance in hepatocellular carcinoma: a bioinformatics study based on validated resistance-related genes |
| Q38133568 | Understanding and targeting resistance to anti-angiogenic therapies |
| Q38795359 | Undifferentiated embryonal sarcoma of the liver with an unusual presentation: case report and review of the literature |
| Q58806076 | Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights |
| Q36097135 | Unusual metastases of gastrointestinal stromal tumor and genotypic correlates: Case report and review of the literature |
| Q34348270 | Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib |
| Q41598539 | Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases |
| Q52643529 | Updates on immunotherapy for colorectal cancer. |
| Q92486899 | Upper gastrointestinal neoplasia in familial adenomatous polyposis: prevalence, endoscopic features and management |
| Q102155255 | Upregulation of ERCC6L is associated with tumor progression and unfavorable prognosis in hepatocellular carcinoma |
| Q38859471 | Use of molecular studies for treatment of metastatic pleomorphic large cell pancreatic cancers-a novel strategy |
| Q40606645 | Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience |
| Q37525349 | Usefulness and feasibility of endoscopic submucosal dissection for colorectal tumor: a nationwide multicenter retrospective study in Korea. |
| Q90041928 | Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma |
| Q37677549 | Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer |
| Q41598652 | Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study |
| Q55714403 | Utilization of intensity modulated radiation therapy for anal cancer in the United States. |
| Q55025183 | Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States. |
| Q102155247 | Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients |
| Q36666690 | Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. |
| Q92645701 | Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity |
| Q33593219 | Viral hepatitis and hepatocellular carcinoma: etiology and management |
| Q89579793 | Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization |
| Q90042012 | Walking to recovery: the effects of missed ambulation events on postsurgical recovery after bowel resection |
| Q112277242 | Weighted gene co-expression network analysis reveals prognostic and diagnostic significance of PAQR4 in patients with early and late hepatocellular carcinoma |
| Q36097254 | What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer |
| Q61804245 | What to expect with major vascular reconstruction during Whipple procedures: a single institution experience and literature review |
| Q94602747 | Which size is the best cutoff for primary small gastric gastrointestinal stromal tumor? |
| Q38859285 | Widespread osteoblastic metastases and marked elevation of CA19-9 as a presentation of signet ring cell gastric carcinoma |
| Q92486866 | Yield of endoscopy of the lower digestive tract in relation to ethnic descent |
| Q125825833 | ZIC5 promotes human hepatocellular carcinoma cell proliferation through upregulating COL1A1 |
| Q36352462 | c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases |